Literature DB >> 9973106

Inability of bone turnover marker as a strong prognostic indicator in prostate cancer patients with bone metastasis: comparison with the extent of disease (EOD) grade.

S Akimoto1, Y Furuya, K Akakura, J Shimazaki, H Ito.   

Abstract

BACKGROUND: Although clinical investigations of bone turnover markers in prostate cancer patients have been conducted, the relationships of pretreatment levels of the markers to the prognosis of patients with bone metastasis has not been fully examined.
METHODS: The serum levels of carboxy-terminal propeptide of type I procollagen (PICP) and carboxy-terminal telopeptide of type I collagen (ICTP), alkaline phosphatase (ALP), and prostate-specific antigen (PSA) were examined in 48 untreated prostate cancer patients with bone metastasis, and the prognoses of the patients were evaluated using univariate and multivariate analyses.
RESULTS: The patients with low PICP or ALP values had significantly better outcomes in terms of cause-specific survival compared to the patients with high PICP or ALP values. There was no significant difference in survival between patients with high and low ICTP or PSA values. The multivariate analysis of PICP, ICTP, ALP, PSA, and extent of disease (EOD) grade revealed that only the EOD grade was an important prognostic indicator for survival.
CONCLUSIONS: These results demonstrate that the extent of bone metastasis evaluated by bone scintigrams is a more important prognostic indicator than are the serum biochemical markers of bone turnover.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 9973106     DOI: 10.1002/(sici)1097-0045(19990101)38:1<28::aid-pros3>3.0.co;2-m

Source DB:  PubMed          Journal:  Prostate        ISSN: 0270-4137            Impact factor:   4.104


  5 in total

1.  Predictive value of the clinically and scintigraphically important bone lesions in hormone-refractory prostate cancer (HRPC).

Authors:  Athanasios Zafeirakis; Georgios S Limouris
Journal:  Clin Transl Oncol       Date:  2009-11       Impact factor: 3.405

2.  Predictive implications of bone turnover markers after palliative treatment with (186)Re-HEDP in hormone-refractory prostate cancer patients with painful osseous metastases.

Authors:  Athanasios Zafeirakis; Georgios Papatheodorou; Athanasios Arhontakis; Athanasios Gouliamos; Lambros Vlahos; Georgios S Limouris
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-01       Impact factor: 9.236

3.  Significance of serum osteoprotegerin and receptor activator of nuclear factor κB ligand in Japanese prostate cancer patients with bone metastasis.

Authors:  Naoto Kamiya; Hiroyoshi Suzuki; Takumi Endo; Makoto Takano; Masashi Yano; Makito Naoi; Koji Kawamura; Takashi Imamoto; Masaharu Takanami; Tomohiko Ichikawa
Journal:  Int J Clin Oncol       Date:  2011-02-16       Impact factor: 3.402

4.  An elevated serum miR-141 level in patients with bone-metastatic prostate cancer is correlated with more bone lesions.

Authors:  Hai-Liang Zhang; Xiao-Jian Qin; Da-Long Cao; Yao Zhu; Xu-Dong Yao; Shi-Lin Zhang; Bo Dai; Ding-Wei Ye
Journal:  Asian J Androl       Date:  2013-02-04       Impact factor: 3.285

5.  Prognostic value of alkaline phosphatase in hormone-sensitive prostate cancer: a systematic review and meta-analysis.

Authors:  Keiichiro Mori; Florian Janisch; Mehdi Kardoust Parizi; Hadi Mostafaei; Ivan Lysenko; Dmitry V Enikeev; Shoji Kimura; Shin Egawa; Shahrokh F Shariat
Journal:  Int J Clin Oncol       Date:  2019-11-25       Impact factor: 3.402

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.